THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Julius Remenar et al.

Serial No.:

10/601,092

Group No.:

1614

Filed:

06/20/2003

Examiner:

For:

PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION

Attorney Docket Number:

TPIP017

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits.

10/28/2004 HALI11

00000042 10601092

01 FC:1806

180.00 DA

A copy of a PCT International Search Report from a counterpart application is enclosed.

Legible copies of all items listed in Form PTO-1449 accompany this information disclosure

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify that under 37 CFR §1.8(a) that this correspondence is being deposited on October 32, 3004 with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(JPW)

statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c)(2). The Commissioner is hereby authorized to charge this fee of \$180.00 to Deposit Account No. 502626.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

Date Oct 21, 2004

By:

Paul Burgess

Registration No. 53,852

Transform Pharmaceuticals, Inc.

29 Hartwell Avenue

Lexington, MA 02421

Tel. #(781) 863-7816

Fax #(781) 863-7208

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

PADE

Sheet 1

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/601,092		
Filing Date	06/20/2003		
First Named Inventor	Julius Remenar		
Art Unit	1614		
Examiner Name			
Attorney Docket Number	TDID017		

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 4,008,321	02-15-1977	Kamishita et al.	
		^{US-} 4,853,379	08-01-1989	Shroot et al.	
		US- 5,641,512	06-24-1997	Cimiluca	
		^{US-} 6,420,394	07-16-2002	Supersaxo	
		US-			
	İ	US-			
		US-			***************************************
		US-			
		US-		1	
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
		WO 95/23596	09-08-1995	The Boots Co		
						<u> </u>
····	ļ					<u> </u>
						<u></u>

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pa no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 14

Sheet

(Use as many sheets as necessary)

2 of

Complete if Known		
Application Number	10/601,092	
Fillng Date	06/20/2003	
First Named Inventor	Julius Remenar	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	TPIP017	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Database, WPI, Section Ch, Week 197936, Derwent Publications Ltd., London, GB, Class B02, AN 1979-65538B XP002282989 & JP 54 095589 A (Sumitomo) 1979 abstract	
		Fung et al., Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates, Chem. Farm. Bull., 22(2), pgs. 454-458 (1974)	
		Rubino et al., Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs", Int. J. of Pharma., 65, pgs. 141-145 (1990)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.